Bevacizumab plus Fotemustine as First-line Treatment in Metastatic Melanoma Patients: Clinical Activity and Modulation of Angiogenesis and Lymphangiogenesis Factors
Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Andrea Anichini(Fondazione IRCCS Istituto Nazionale dei Tumori), Nicola Pimpinelli(University of Florence), Paola Morosini(Ospedale Maggiore di Lodi), Lorenza Di Guardo(Fondazione IRCCS Istituto Nazionale dei Tumori), Stefania Canova, Tania Perrone(Italfarmaco (Italy)), Roberta Mortarini(Scripps Research Institute), Emilio Bajetta(Fondazione Lanza), Davide Bedognetti(Sidra Medical and Research Center), Paola Queirolo, M. R. Sertoli(Italfarmaco (Italy))
Cited by 59
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
|New England Journal of Medicine|2004|1.8k